AstraZeneca and Bristol-Myers Squibb received a complete-response letter from the FDA for type 2 diabetes medicine dapagliflozin.
The agency wants more clinical data and possibly further testing, the companies said.
FDA advisers had refused to endorse dapagliflozin, citing risks of cancer and liver injury.

Full Story:

Related Summaries